28
Oct
2025

Siegfried AG

Exhibitor at CPHI Frankfurt 2025 stand 6.0B6, Contract Manufacturing and Services
About Us

Siegfried is a preferred partner for complete integrated Drug Substance and Drug Product services with production capabilities worldwide. Creating, improving and manufacturing formulations is our passion. Our professionalism is pivotal for your project throughout the entire life cycle. Our offering, the combination of inherited technical know-how and expertise, is unique for a supplier of development and manufacturing services.
Our Drug Substance services include Custom Development and Contract Manufacturing for both APIs and intermediates. In addition, we offer a multiclient API portfolio (including controlled substances) with drug master files and patented technologies.
Our Drug Product clients benefit from a broad spectrum of dosage forms and technologies like oral solids, inhalative products, opthalmics and sterile ointments. Drug Product services include Custom Development and Contract Manufacturing for the dosage forms mentioned above.
Siegfried enhanced its Drug Product capabilities with the acquisition of two Novartis sites near Barcelona and the establishment of a center of excellence for developing and optimizing formulations. Thus, we expanded our competency with high potent Drug Product development and manufacturing down to an OEL of 1µg/m3, next to capsules with APIs (down to 0.1 µg/m3).
Complex oral drug delivery systems or solubility increasing of APIs (e.g. nanomilling or spray drying) belong to our core competences. In the field of steriles, we are experienced with fill and finish of vaccines and biologic compounds. Furthermore, we can offer dry powder inhalator capsules.
Siegfried has 11 GMP approved sites worldwide spanning both the eastern and western hemispheres. Our Drug Substance sites are located in Zofingen (Switzerland), Pennsville (US), Nantong (China), Minden (Germany), Evionnaz (Switzerland) and St. Vulbas (France). Our Drug Product locations are in H...

  • CH
  • 2015
    On CPHI since
  • 3
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 6.0B6, Contract Manufacturing and Services

Products Featured at CPHI Frankfurt 2025

  • API portfolio

    Product API portfolio

    Siegfried offers a broad portfolio of active pharmaceutical ingredients including controlled substances, focused on anesthetics, analgesics, decongestants, addiction treatment, and a variety of other therapeutic indications. In addition, we offer pharma grade caffeine for use in pharmaceutical and nutritio...
  • Exclusive synthesis

    Product Exclusive synthesis

    We are experts in process development and manufacturing of exclusive active pharmaceutical ingredients and intermediates.

    Your most trusted partner for exclusive synthesis:- More than 150 years experience in process development and production of customized APIs
    - Secure and relia...
  • Highly potent oral solids

    Product Highly potent oral solids

    Our team has multiple decades of experience offering a wide range of services from development to manufacturing at the highest level of quality compliance. Our technologies include dry and wet granulation processing, blending, capsule filling, tableting, coating, blistering and bottling.

    We are ...
  • Steriles

    Product Steriles

    We are your expert in sterile and aseptic manufacturing, where quality is paramount.
    Your most trusted partner for sterile and aseptic fill & finish:
    - Extensive knowledge and experience in process and analytical development
    - Unbeatable speed to market, without compromising on quality
    - ...
  • Inhalation products

    Product Inhalation products

    Siegfried is an expert in manufacturing capsule-based dry powder inhalation products.
    Your most trusted partner for inhalation products:
    - Experience handling HPAPIs, low-dose encapsulation and aerodynamic testing
    - State-of-the-art facilities and equipment ensuring highest quality inhalation pr...
  • Ophthalmics

    Product Ophthalmics

    Siegfried is your expert in ophthalmic formulations with outstanding manufacturing and packaging capabilities. 

    Your most trusted partner for ophthalmics:
    - Dedicated Development Center offering development and scale up services
    - 95+ years experience asa reliable ophthalmic partner
    - ...
  • Oral solids

    Product Oral solids

    Our experienced formulation development teams support commercial development and manufacturing strategies across a wide range of drug programs.
    Your most trusted partner for oral solids:
    - Extensive knowledge in highly potent APIs
    - Resilient and reliable supply chains supported by our global ne...

Siegfried AG Resources (7)

  • Webinar From Lab to Commercial Production -How to Combat Challenges in OSD High Potency Products Development

    Highly Potent APIs are a rapidly growing segment of the global pharmaceutical industry, and they are acquiring a significant relevance into the development space. The importance to understand the challenges around development of High Potency Oral solids formulations, are the key to ensure a right scale-up and launch Risk-based approach: measuring the risk, not the hazard Challenges for High potency products handling. Importance of select the adequate partner Development of secure and scalable process in high containment environment
  • Webinar Building a Collaborative Supply Chain for Biological Products: A Roadmap for the Future

    The Covid-19 Pandemic forced us to learn new ways of collaborating and innovating to solve a global crisis - what can we learn and leverage from this experience as we adapt to a 'new normal'?
    Amazing scientific development and break-throughs are evolving faster than ever, with new advanced treatment options for patients being developed at unprecedented speed. All of us involved in manufacturing and supply need to rethink how we collaborate, deliver medicines and learn faster.
    No one company can solve this alone - requiring us to collaborate, innovate and learn in new ways. What does this change really mean for us? Welcome to engage in a discussion, sharing case study data and recent insights in the middle of an industry learning journey.
  • Webinar Process Optimization for Viral Vector Manufacturing

    Though viral vectors are used extensively in cell and gene therapy, the challenges of manufacturing such complex biologics at industrial scale is still a limitation to its broader use.
    Dr. Ayuso will speak about how upstream and downstream process optimization using design of experiments (DOE), a platform approach and end-to-end capabilities can tackle manufacturing challenges and help to expedite drug development.
  • Webinar Keynote Address: Next-Gen Biomanufacturing

    Join Asklepios BioPharmaceutical's former CEO Shelia Ann Mikhail, where she will Set the Scene for the latest innovations and developments affecting the Biomanufacturing Landscape
  • Webinar Overcoming Challenges in Transferring a Sterile Biologics Drug Product to a CDMO

    Ensuring quality and compliance in bio-manufacturing Closing gaps in development data prior to the first GMP production Adjusting manufacturing processes throughout the course of a site-to-site transfer Fulfilling special requirements on container closure systems for biologics Transferring analytical methods for drug products and drug substances
  • Webinar Building a Collaborative Supply Chain for Biological Products: A Roadmap for the Future

    The Covid-19 Pandemic forced us to learn new ways of collaborating and innovating to solve a global crisis - what can we learn and leverage from this experience as we adapt to a new normal? Amazing scientific development and break-throughs are evolving faster than ever, with new advanced treatment options for patients being developed at unprecedented speed. All of us involved in manufacturing and supply need to rethink how we collaborate, deliver medicines and learn faster.
    No one company can solve this alone - requiring us to collaborate, innovate and learn in new ways. What does this change really mean for us? Welcome to engage in a discussion, sharing case study data and recent insights in the middle of an industry learning journey.
  • Webinar "Panel: Strategies for Commercialising Cell and Gene Therapies"

    Manufacturers face unique quality challenges that can hinder progress. In this session, discover quality challenges in Cell and Gene Therapy (CGT) and learn common practices for overcoming them:
    Where are all the approvals? Understanding unique manufacturing challenges for Autologous Cell Therapies How does development by design, quality by design, and Cell Therapy COGs converge in this new space? Creating a Cell Therapy technology roadmap to address challenges and drive speed-to-market